Literature DB >> 19123733

Measuring extent of ductal carcinoma in situ in breast excision specimens: a comparison of 4 methods.

Andrea Grin1, Garnet Horne, Marguerite Ennis, Frances P O'Malley.   

Abstract

CONTEXT: Measuring the extent of nonpalpable ductal carcinoma in situ (DCIS) in a breast specimen is challenging but important because it influences patient management. There is no standardized method for estimating the extent of DCIS, although serial sequential sampling with mammographic correlation is considered an accurate method.
OBJECTIVE: To estimate the extent of DCIS using various methods and to compare these estimations with the extent as determined by the serial sequential sampling method.
DESIGN: A total of 78 primary breast excisions with DCIS were retrospectively reviewed. All specimens had been sampled using the serial sequential sampling method, which involved mapping the location of each block on the sliced specimen radiograph and calculating the extent through 3-dimensional reconstruction. The other measures for estimating extent included (1) calculating size based on areas of calcification, (2) recording the number of blocks involved by DCIS and multiplying that number by 0.3 cm, and (3) measuring the largest extent of DCIS on a single slide.
RESULTS: All 3 alternative methods tended to underestimate the DCIS. Discrepancies became more pronounced as size increased. The percentage of cases estimated to within 1 cm of the serial sequential sampling method were 81%, 72%, and 50%, respectively, for the calcification, blocks, and single-slide methods; differences of more than 2 cm were seen in 9%, 8%, and 30% of cases, respectively.
CONCLUSIONS: The single-slide method performed poorly and should be used only when DCIS is limited to a single slide. Although the calcification and the blocks methods gave better estimates, both produced substantial underestimates and/or overestimates that could affect clinical decision making.

Entities:  

Mesh:

Year:  2009        PMID: 19123733     DOI: 10.5858/133.1.31

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  7 in total

Review 1.  Is DCIS breast cancer, and how do I treat it?

Authors:  N Bijker; M Donker; J Wesseling; G J den Heeten; E J Th Rutgers
Journal:  Curr Treat Options Oncol       Date:  2013-03

2.  Automated reconstruction algorithm for identification of 3D architectures of cribriform ductal carcinoma in situ.

Authors:  Kerri-Ann Norton; Sameera Namazi; Nicola Barnard; Mariko Fujibayashi; Gyan Bhanot; Shridar Ganesan; Hitoshi Iyatomi; Koichi Ogawa; Troy Shinbrot
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

3.  Microinvasive breast cancer and the role of sentinel lymph node biopsy.

Authors:  Sean M Hacking; Kara-Lynne Leonard; Dongling Wu; Mara Banks; Theresa Graves; Lijuan Wang; Evgeny Yakirevich; Yihong Wang
Journal:  Sci Rep       Date:  2022-07-20       Impact factor: 4.996

4.  The role of large-format histopathology in assessing subgross morphological prognostic parameters: a single institution report of 1000 consecutive breast cancer cases.

Authors:  Tibor Tot
Journal:  Int J Breast Cancer       Date:  2012-10-21

5.  Imaging-assisted large-format breast pathology: program rationale and development in a nonprofit health system in the United States.

Authors:  F Lee Tucker
Journal:  Int J Breast Cancer       Date:  2012-12-17

6.  Characteristics of ultrasonographic images of ductal carcinoma in situ with abnormalities of the ducts.

Authors:  Kanako Ban; Hiroko Tsunoda; Takanori Watanabe; Setsuko Kaoku; Takuhiro Yamaguchi; Ei Ueno; Koichi Hirokaga; Kumiko Tanaka
Journal:  J Med Ultrason (2001)       Date:  2019-10-26       Impact factor: 1.314

7.  Clinical performance of contrast-enhanced spectral mammography in pre-surgical evaluation of breast malignant lesions in dense breasts: a single center study.

Authors:  Anna Bozzini; Luca Nicosia; Giancarlo Pruneri; Patrick Maisonneuve; Lorenza Meneghetti; Giuseppe Renne; Andrea Vingiani; Enrico Cassano; Mauro Giuseppe Mastropasqua
Journal:  Breast Cancer Res Treat       Date:  2020-08-28       Impact factor: 4.872

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.